American Century Investments One Choice 2050 Portfolio Investor Class (ARFVX) befektetési alap jegyének ára és hírek

FőoldalARFVX • befektetési alap

American Century Investments One Choice 2050 Portfolio Investor Class

14,95 $

ápr. 10. · USD · MUTF · Felelősségkizárás

American Century Investments One Choice 2045 Portfolio Investor Class

17,99 $

AROIX0,11%

American Century Investments One Choice In Retirement Portfolio Investor Class

12,68 $

ARTOX0,079%

American Century Investments One Choice 2030 Portfolio Investor Class

12,39 $

ARCVX0,16%

American Century Investments One Choice 2035 Portfolio Investor Class

16,31 $

ARYIX0,12%

American Century Investments One Choice 2040 Portfolio Investor Class

13,51 $

ARDVX0,15%

American Century Investments One Choice 2055 Portfolio Investor Class

17,50 $

AREVX0,17%

American Century Investments One Choice 2060 Portfolio Investor Class

16,44 $

ARGVX0,18%

American Century Value Fund Investor Class

8,48 $

TWVLX0,82%

American Century Growth Fund Investor Class

53,58 $

TWCGX0,17%

American Century Diversified Bond Fund Investor Class

9,19 $

ADFIX0,11%

Befektetési alap

Előző zárás

14,97 $

Tárgyévi göngyölített hozam

-1,63%

Költséghányad

0,88%

Kategória

Target Date

Morningstar-besorolás

Nettó eszközérték

274,16 M USD

Hozam

2,31%

Kezdeti kiadás

Indulás dátuma

2008. máj. 30.

Piaci hírek

Investor's Business Daily

3 órával ezelőtt

U.S.-Iran Talks Continue; Three Titans In Buy Areas

Inside the S&P 500’s 7-Day Rally: How Two Chip Stocks Fueled the Surge

‘One basis point': Benchmark says a fraction of NYSE’s $44 trillion market could drive Securitize growth

6,50%

Simply Wall Street

3 perccel ezelőtt

Is ICON (NasdaqGS:ICLR) Offering An Opportunity After Recent Share Price Volatility?

Eric Swider resigns from Trump Media board

DJT

1,40%

Belleville News-Democrat

8 órával ezelőtt

New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holdings (NASDAQ:YYGH), Vivos Therapeutics (NASDAQ:VVOS), and Stardust Power (NASDAQ

NDAQ

1,25%